 Joan O'Keefe
Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fragile X Syndrome | 7 | 2020 | 148 | 4.310 |
Why?
| | Ataxia | 6 | 2020 | 68 | 4.240 |
Why?
| | Tremor | 6 | 2020 | 98 | 4.150 |
Why?
| | Fragile X Mental Retardation Protein | 5 | 2016 | 87 | 1.790 |
Why?
| | Gait Disorders, Neurologic | 3 | 2020 | 132 | 1.650 |
Why?
| | Heterozygote | 4 | 2020 | 99 | 1.580 |
Why?
| | Accidental Falls | 2 | 2020 | 101 | 1.540 |
Why?
| | Postural Balance | 3 | 2020 | 109 | 0.990 |
Why?
| | Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.920 |
Why?
| | Nootropic Agents | 1 | 2020 | 14 | 0.910 |
Why?
| | Gait | 4 | 2020 | 361 | 0.900 |
Why?
| | Huntington Disease | 1 | 2020 | 56 | 0.870 |
Why?
| | Phenotype | 3 | 2016 | 347 | 0.850 |
Why?
| | Movement Disorders | 2 | 2020 | 132 | 0.850 |
Why?
| | Cyclodextrins | 1 | 2018 | 5 | 0.800 |
Why?
| | Niemann-Pick Disease, Type C | 1 | 2018 | 10 | 0.790 |
Why?
| | Executive Function | 1 | 2018 | 93 | 0.780 |
Why?
| | Severity of Illness Index | 3 | 2020 | 1169 | 0.670 |
Why?
| | Receptors, Estrogen | 5 | 1995 | 54 | 0.620 |
Why?
| | Hyperkinesis | 1 | 2013 | 12 | 0.590 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2013 | 21 | 0.580 |
Why?
| | Male | 14 | 2020 | 16222 | 0.530 |
Why?
| | Female | 13 | 2020 | 16622 | 0.480 |
Why?
| | Neuropsychological Tests | 4 | 2020 | 1210 | 0.460 |
Why?
| | Cognition Disorders | 1 | 2018 | 1056 | 0.450 |
Why?
| | Aged | 7 | 2020 | 9291 | 0.450 |
Why?
| | Middle Aged | 8 | 2020 | 10510 | 0.450 |
Why?
| | Humans | 12 | 2020 | 27786 | 0.420 |
Why?
| | Biomechanical Phenomena | 3 | 2016 | 685 | 0.410 |
Why?
| | Hippocampus | 4 | 1995 | 276 | 0.390 |
Why?
| | Cognition | 3 | 2020 | 963 | 0.350 |
Why?
| | Parkinson Disease | 3 | 2020 | 1062 | 0.310 |
Why?
| | Pilot Projects | 2 | 2020 | 409 | 0.240 |
Why?
| | Case-Control Studies | 2 | 2020 | 643 | 0.240 |
Why?
| | Retrospective Studies | 2 | 2020 | 2952 | 0.230 |
Why?
| | Time and Motion Studies | 1 | 2020 | 12 | 0.230 |
Why?
| | Glucosylceramidase | 1 | 2020 | 14 | 0.230 |
Why?
| | Arm | 1 | 2020 | 51 | 0.230 |
Why?
| | Adolescent | 2 | 2018 | 2439 | 0.210 |
Why?
| | Range of Motion, Articular | 2 | 2020 | 658 | 0.200 |
Why?
| | Infusions, Spinal | 1 | 2018 | 4 | 0.200 |
Why?
| | Psychomotor Performance | 1 | 2020 | 229 | 0.200 |
Why?
| | Spinal Puncture | 1 | 2018 | 23 | 0.200 |
Why?
| | Mutation | 1 | 2020 | 420 | 0.190 |
Why?
| | Congresses as Topic | 1 | 2016 | 28 | 0.180 |
Why?
| | Brain Tissue Transplantation | 2 | 1993 | 26 | 0.180 |
Why?
| | Posture | 1 | 2016 | 85 | 0.170 |
Why?
| | Motor Activity | 1 | 2020 | 385 | 0.170 |
Why?
| | Computers | 1 | 2015 | 19 | 0.170 |
Why?
| | Animals | 7 | 2016 | 4985 | 0.170 |
Why?
| | Neuroimaging | 1 | 2016 | 93 | 0.170 |
Why?
| | Trinucleotide Repeat Expansion | 1 | 2015 | 33 | 0.170 |
Why?
| | Aged, 80 and over | 2 | 2016 | 4766 | 0.170 |
Why?
| | Early Diagnosis | 1 | 2015 | 75 | 0.170 |
Why?
| | Animals, Newborn | 3 | 1993 | 72 | 0.170 |
Why?
| | Reaction Time | 1 | 2015 | 113 | 0.160 |
Why?
| | Monitoring, Physiologic | 1 | 2015 | 92 | 0.160 |
Why?
| | Sexual Behavior, Animal | 1 | 1994 | 3 | 0.160 |
Why?
| | Pituitary-Adrenal System | 1 | 1994 | 11 | 0.160 |
Why?
| | Receptors, Progesterone | 1 | 1994 | 36 | 0.160 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 1994 | 22 | 0.160 |
Why?
| | Regression Analysis | 1 | 2015 | 313 | 0.160 |
Why?
| | Cerebral Cortex | 2 | 1993 | 180 | 0.160 |
Why?
| | Arousal | 1 | 1994 | 54 | 0.160 |
Why?
| | Time Factors | 1 | 2020 | 1802 | 0.150 |
Why?
| | RNA, Messenger | 1 | 1995 | 354 | 0.150 |
Why?
| | Disability Evaluation | 1 | 2016 | 318 | 0.150 |
Why?
| | Task Performance and Analysis | 1 | 2013 | 57 | 0.140 |
Why?
| | Cerebellar Diseases | 1 | 2013 | 11 | 0.140 |
Why?
| | Disease Progression | 1 | 2016 | 799 | 0.140 |
Why?
| | Rats | 6 | 1995 | 938 | 0.140 |
Why?
| | Movement | 1 | 2013 | 165 | 0.140 |
Why?
| | Activities of Daily Living | 1 | 2015 | 437 | 0.130 |
Why?
| | Neurons | 2 | 1995 | 380 | 0.120 |
Why?
| | Cohort Studies | 1 | 2016 | 1773 | 0.120 |
Why?
| | Adult | 2 | 2015 | 9100 | 0.120 |
Why?
| | Treatment Outcome | 1 | 2020 | 3508 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 1 | 2016 | 1163 | 0.120 |
Why?
| | Child | 1 | 2013 | 1372 | 0.110 |
Why?
| | Young Adult | 1 | 2013 | 2047 | 0.090 |
Why?
| | Fetal Tissue Transplantation | 2 | 1993 | 33 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 2 | 1995 | 480 | 0.070 |
Why?
| | Estradiol | 2 | 1993 | 46 | 0.070 |
Why?
| | Pregnancy | 2 | 1993 | 400 | 0.060 |
Why?
| | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 1995 | 1 | 0.040 |
Why?
| | N-Methylaspartate | 1 | 1995 | 4 | 0.040 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 1995 | 25 | 0.040 |
Why?
| | Receptors, AMPA | 1 | 1995 | 13 | 0.040 |
Why?
| | Sex Differentiation | 1 | 1995 | 2 | 0.040 |
Why?
| | Blotting, Northern | 1 | 1995 | 30 | 0.040 |
Why?
| | DNA, Complementary | 1 | 1995 | 35 | 0.040 |
Why?
| | In Situ Hybridization | 1 | 1995 | 61 | 0.040 |
Why?
| | Corticotropin-Releasing Hormone | 1 | 1994 | 7 | 0.040 |
Why?
| | Adrenocorticotropic Hormone | 1 | 1994 | 11 | 0.040 |
Why?
| | Rats, Inbred Strains | 2 | 1992 | 47 | 0.040 |
Why?
| | Cytosol | 2 | 1992 | 61 | 0.040 |
Why?
| | Preoptic Area | 1 | 1993 | 6 | 0.040 |
Why?
| | Transplantation, Heterotopic | 1 | 1993 | 13 | 0.040 |
Why?
| | Gene Expression | 1 | 1995 | 263 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 823 | 0.040 |
Why?
| | Frontal Lobe | 1 | 1993 | 85 | 0.040 |
Why?
| | Brain Mapping | 1 | 1994 | 186 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 1994 | 329 | 0.030 |
Why?
| | Aging | 2 | 1993 | 1402 | 0.030 |
Why?
| | Age Factors | 1 | 1995 | 869 | 0.030 |
Why?
| | Calcium | 1 | 1995 | 488 | 0.030 |
Why?
| | Ethinyl Estradiol | 1 | 1990 | 2 | 0.030 |
Why?
| | Estrogen Antagonists | 1 | 1990 | 3 | 0.030 |
Why?
| | Chromatography, Affinity | 1 | 1990 | 9 | 0.030 |
Why?
| | Diethylstilbestrol | 1 | 1990 | 4 | 0.030 |
Why?
| | Cell Nucleus | 1 | 1990 | 93 | 0.030 |
Why?
| | Kinetics | 1 | 1990 | 273 | 0.030 |
Why?
| | Sex Factors | 1 | 1990 | 498 | 0.030 |
Why?
| | Receptors, Glutamate | 1 | 1995 | 4 | 0.010 |
Why?
| | Glutamic Acid | 1 | 1995 | 35 | 0.010 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 1995 | 35 | 0.010 |
Why?
| | Cells, Cultured | 1 | 1995 | 778 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 1992 | 271 | 0.010 |
Why?
|
|
O'Keefe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|